期刊文献+

miR-450a-5p在浆液性卵巢癌中的表达及临床意义 被引量:2

The Expression and Clinical Significance of miR-450a-5p in Serous Ovarian Cancer
原文传递
导出
摘要 目的:检测miR-450a-5p在浆液性卵巢癌中的表达情况,并分析miR-450a-5p的表达与浆液性卵巢癌临床病理特征之间的关系,探讨其在浆液性卵巢癌发生、发展中的意义。方法:采用实时荧光定量PCR技术,检测101例浆液性卵巢癌组织及对照50例正常输卵管伞端组织中miR-450a-5p的表达情况,并分析miR-450a-5p表达水平与临床病理特征之间的关系。实验数据采用统计学软件进行分析。结果:miR-450a-5p在浆液性卵巢癌组织中的表达量显著低于正常输卵管组织对照组(P<0.01)。miR-450a-5p的表达水平与浆液性卵巢癌临床病理特征之间差异均无统计学意义(P>0.05)。结论:miR-450a-5p可能作为抑癌基因,在卵巢癌的发生、发展中发挥重要作用,进一步的研究有望为浆液性卵巢癌的早期诊断及个体化治疗提供新的理论依据。 Objective: To investigate the expression of miR-450a-5p in serous ovarian cancer, and analyze the correlation of its expression with clinicpathological features and investigate the significance of miR-450a-5p in ovarian cancer carcinogenesis and development. Methods: Quantitative real-time PCR was used to assess the expression of miR-450a-5p in 101 serous ovarian cancer tissues and 50 normal fimbria of fallopian tube tissues, and the results were assessed with statistic analysis. Results: The expression of miR-450a-5p in serous ovarian cancer tissues down-regulated significantly than that in normal funbria of fallopian tube tissues (P 〈 0.01). There was no significant difference for expression ofmiR-450a-5p with clinicopathological features in serous ovarian cancer (P〉 0.05). Conclusion: miR-450a-5p may play an important role as a tumor-suppressor in the occurrence and development of serous ovarian cancer and may provide new basic theories for the earlier diagnosis and target treatment of serous ovarian cancer.
出处 《现代生物医学进展》 CAS 2014年第17期3240-3243,共4页 Progress in Modern Biomedicine
基金 教育部留学回国人员科研启动基金(HG3310) 陕西省科技攻关课题(2007K09-09) 陕西省科学技术研究发展计划项目(2014k11-01-01-25)
关键词 浆液性卵巢癌 输卵管伞端组织 miR-450a-5p 实时荧光定量PCR Serous ovarian cancer Fimbria of fallopian tube miR-450a-5p Real-time fluorescent quantitative PCR
  • 相关文献

参考文献24

  • 1高雯,臧荣余,王雁,杨丽娜,刘杨,亓子豪,尹胜,杨恭.人类输卵管上皮永生化细胞系的建立及鉴定[J].中国癌症杂志,2013,23(4):241-247. 被引量:8
  • 2Chen EY, Mehra K, Mehrad M, et al. Secretory cell outgrowth, PAX2and serous carcinogenesis in the Fallopian tube [J]. J Pathol, 2010, 222(1): 110-116.
  • 3Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary.FIGO 26th Annual Report on the Results of Treatment in GynecologicalCancer [J]. Int J Gynaecol Obstet, 2006, 95(Suppl 1): S161-S192.
  • 4Hanna L, Adams M. Prevention of ovarian cancer [J]. Best Pract ResClin Obstet Gynaecol, 2006, 20(2): 339-362.
  • 5Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA CancerJ Clin, 2009, 59(4): 225-249.
  • 6Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs [J].Science, 2005, 309(5740): 1519-1524.
  • 7Berezikov E, Guryev V, van de Belt J, et al. Phylogenetic shadowingand computational identification of human microRNA genes [J]. Cell,2005, 120(1): 21-24.
  • 8Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages oftumorigenesis correlate with hallmark capabilities of cancer [J]. GenesDev, 2009, 23(18): 2152-2165.
  • 9Levanon K, CrumC, Drapkin R. New insights into the pathogenesis ofserous ovarian cancer and its clinical impact[J]. J Clin Oncol, 2008, 26(32): 5284-5293.
  • 10Erickson BK, Conner MG, Landen CJ. The role of the fallopian tubein the origin of ovarian cancer [J]. Am J Obstet Gynecol, 2013, 209(5): 409-414.

二级参考文献14

  • 1LI J, FADARE O, XIANG L, et al. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesi [ J ] . J Hematol Oncol, 2012, 5: 8.
  • 2LI N F, WILBANKS G, BALKWILL1 F, et al. A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro [ J ] . Lab Invest, 2004, 84(7): 923-931.
  • 3SHAY J W, WRIGHT W E. Senescence and immortalization: role of telomeres and telomerase [ J ] . Carcinogenesis, 2005, 26(5): 867-874.
  • 4YE X, ZERLANKO B, ZHANG R, et al. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASFla- mediated formation of senescence-associated heterochromatin foci [ J ]. Mol Cell Biol, 2007, 27(7): 2452-2465.
  • 5HAFERKAMP S, TRAN S L, BECKER T M, et al. The relative contributions of the p53 and pRb pathways in oncogene- induced melanocyte senescence [ J ] . Aging (Albany NY), 2009, 1(6): 542-556.
  • 6VERMEULEN K, VAN BOCKSTAELE D R, BERNMAN Z N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer [ J ] . Cell Prolif, 2003, 36(3): 131-149.
  • 7RAMIREZ R D, SHERIDAN S, GIRAAD L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins [ J ] . Cancer Res, 2004, 64(24): 9027-9034.
  • 8MASUTOMI K, YU E Y, KHURTS S, et al. Telomerase maintains telomere structure in normal human cells [ J ] . Cell, 2003, 114(2): 241-253.
  • 9SEALEY, D C, ZHENG L, TABOSKI M A, et al. The N-terminus of hTERT contains a DNA-binding domain and is required for telomerase activity and cellular immortalization [ J ]. Nucleic Acids Res, 2010, 38(6): 2019-2035.
  • 10SHAN W W, LIU J.Epithelial ovarian cancer: focus on genetics and animal models [ J ] . Cell Cycle, 2009, 8(5): 731-735.

共引文献7

同被引文献33

  • 1Chen EY,Mehra K,Mehrad M,et al.Secretory cell outgrowth,PAX2 and serous carcinogenesis in the Fallopian tube[J].J Pathol,2010,222(1):110-116.
  • 2Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
  • 3Mei L,Chen H,Wei DM,et al.Maintenance chemotherapy for ovarian cancer[J].Cochrane Database Syst Rev,2010,9:D7414.
  • 4Heintz AP,Odicino F,Maisonneuve P,et al.Carcinoma of the ovary.FIGO 26th annual report on the results of treatment in gynecological cancer[J].Int J Gynaecol Obstet,2006,95(Suppl 1):S161-S192.
  • 5Aletti GD,Gallenberg MM,Cliby WA,et al.Current management strategies for ovarian cancer[J].Mayo Clin Proc,2007,82(6):751-770.
  • 6Clarke-Pearson DL.Clinical practice.screening for ovarian cancer[J].N Engl J Med,2009,361(2):170-177.
  • 7Zamore PD,Haley B.Ribognome:the big world of small RNAs[J].Science,2005,309:1519-1524.
  • 8Li J,Fadare O,Xiang L,et al.Ovarian serous carcinoma:recent concepts on its origin and carcinogenesis[J].J Hematol Oncol,2012,5(1):8-19.
  • 9Liu Z,Liu J,Segura MF,et al.MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma[J].J Pathol,2012,228(2):204-215.
  • 10Mcmillen BD,Aponte MM,Liu Z,et al.Expression analysis of miR182 and its associated target genes in advanced ovarian carcinoma[J].Mod Pathol,2012,25(12):1644-1653.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部